SlideShare uma empresa Scribd logo
1 de 20
[object Object]
 The major causes of inter subject pharmacokinetic  variability are  :- 	,[object Object]
Age          1.Drug metabolism in new born        2.Plasma protein bonding in new born        3.Renal excretion in new born        4.Drug metabolism in children ,[object Object]
Disease,[object Object]
[object Object]
Drug binding, metabolism, and excretion may change as a function of age.
The study panel was divided into 5 groups:                        		              Newborns (2 to 3 days) 	          Infants (1 to 12 months)               Children (4 to 9 years)                Adults (16 to 37 years)                Elderly subjects (more than 70 years)
[object Object]
Clearance increased from 0.9 to 2.5 ml/min. when comparing patient 1 to 8 days old with patient 9 to 30  days old.
The mean clearance of ceftriaxone in children ranging in age from 1 to 12 months and from 1 to 6 years was 6.2 ml/min. and 9.1 ml/min. respectively.
The  18 to 49 years old age group had the highest clearance of ceftriaxone, 17 ml/min. ,[object Object]
Very elderly patients 75 to 92 years of age had an average clearance of about 8 ml/min.,[object Object]
Most of the enzymatic microsomal systems required for drug metabolism are present at birth, but their  concentration are usually lower than adult levels.
In  general drugs subject to  biotransformation are eliminated more slowly in newborn than in adult.,[object Object]
Sulfate conjugation seems to be as efficient in newborns as in adults, but conjugation with glucuronic acid is considerably reduced, reaching adult level only after 3 years of age.
This deficiency is responsible for the serious adverse effects observed in newborn after administration of chloramphenicol a drug that is ordinarily conjugated with glucuroni acid.  ,[object Object]
The amount of unchanged theophylline in urine in premature infants decreases with postnatal age, whereas the excretion of metabolites increases with age. ,[object Object]
In each case binding in plasma protein is level in the newborns than in the adults.
Increase in plasma protein binding is an increase in apparent volume of distribution in the newborn.

Mais conteúdo relacionado

Mais procurados

Dose adjustment in renal disorder
Dose adjustment in renal disorderDose adjustment in renal disorder
Dose adjustment in renal disorderDr. Ankit Gaur
 
Effects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokineticsEffects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokineticsDr. Ramesh Bhandari
 
Drug Induced Liver Disorder
Drug Induced Liver DisorderDrug Induced Liver Disorder
Drug Induced Liver DisorderMerlinMathews3
 
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASESDRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASESDr.Amreen Saba Attariya
 
BASIC PRINCIPLES OF CANCER CHEMOTHERAPY- THIRD PHARM.D
BASIC PRINCIPLES OF CANCER CHEMOTHERAPY- THIRD PHARM.DBASIC PRINCIPLES OF CANCER CHEMOTHERAPY- THIRD PHARM.D
BASIC PRINCIPLES OF CANCER CHEMOTHERAPY- THIRD PHARM.DAPOLLO JAMES
 
Paediatric (pediatrics) medication-drugs therapy in pediatrics
Paediatric (pediatrics) medication-drugs therapy in pediatricsPaediatric (pediatrics) medication-drugs therapy in pediatrics
Paediatric (pediatrics) medication-drugs therapy in pediatricsRavish Yadav
 
FORMULATION FACTORS EFFECTING BIOAVAILABILITY OF DRUGS
FORMULATION FACTORS EFFECTING BIOAVAILABILITY OF DRUGSFORMULATION FACTORS EFFECTING BIOAVAILABILITY OF DRUGS
FORMULATION FACTORS EFFECTING BIOAVAILABILITY OF DRUGSN Anusha
 
Geriatric,obese and pediatric patients Pharmacokinetics
Geriatric,obese and pediatric patients PharmacokineticsGeriatric,obese and pediatric patients Pharmacokinetics
Geriatric,obese and pediatric patients PharmacokineticsAreej Abu Hanieh
 
Applications of pharmacokinetics parameters in disease states
Applications of pharmacokinetics parameters in disease statesApplications of pharmacokinetics parameters in disease states
Applications of pharmacokinetics parameters in disease statesUmair hanif
 
Biopharmaceutical & Pharmacokinetic consideration in the development of Contr...
Biopharmaceutical & Pharmacokinetic consideration in the development of Contr...Biopharmaceutical & Pharmacokinetic consideration in the development of Contr...
Biopharmaceutical & Pharmacokinetic consideration in the development of Contr...SARADPAWAR1
 
Dose adjustment in Renal failure
Dose adjustment in Renal failure Dose adjustment in Renal failure
Dose adjustment in Renal failure Mallinath Paramgond
 
Methods to determine area under curve
Methods to determine area under curveMethods to determine area under curve
Methods to determine area under curveMd.Rakibul Islam
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDr. Ramesh Bhandari
 
DESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptxDESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptxDrAniqaSundas
 
Rate limiting steps in drug absorption
Rate limiting steps in drug absorptionRate limiting steps in drug absorption
Rate limiting steps in drug absorptionC Prakash
 

Mais procurados (20)

Dose adjustment in renal disorder
Dose adjustment in renal disorderDose adjustment in renal disorder
Dose adjustment in renal disorder
 
Effects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokineticsEffects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokinetics
 
Designing of dosage regimen
Designing of dosage regimenDesigning of dosage regimen
Designing of dosage regimen
 
Drug Induced Liver Disorder
Drug Induced Liver DisorderDrug Induced Liver Disorder
Drug Induced Liver Disorder
 
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASESDRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
 
BASIC PRINCIPLES OF CANCER CHEMOTHERAPY- THIRD PHARM.D
BASIC PRINCIPLES OF CANCER CHEMOTHERAPY- THIRD PHARM.DBASIC PRINCIPLES OF CANCER CHEMOTHERAPY- THIRD PHARM.D
BASIC PRINCIPLES OF CANCER CHEMOTHERAPY- THIRD PHARM.D
 
Paediatric (pediatrics) medication-drugs therapy in pediatrics
Paediatric (pediatrics) medication-drugs therapy in pediatricsPaediatric (pediatrics) medication-drugs therapy in pediatrics
Paediatric (pediatrics) medication-drugs therapy in pediatrics
 
FORMULATION FACTORS EFFECTING BIOAVAILABILITY OF DRUGS
FORMULATION FACTORS EFFECTING BIOAVAILABILITY OF DRUGSFORMULATION FACTORS EFFECTING BIOAVAILABILITY OF DRUGS
FORMULATION FACTORS EFFECTING BIOAVAILABILITY OF DRUGS
 
Geriatric,obese and pediatric patients Pharmacokinetics
Geriatric,obese and pediatric patients PharmacokineticsGeriatric,obese and pediatric patients Pharmacokinetics
Geriatric,obese and pediatric patients Pharmacokinetics
 
Dosing in obese patient
Dosing in obese patientDosing in obese patient
Dosing in obese patient
 
Clinical pharmacokinetics
Clinical pharmacokineticsClinical pharmacokinetics
Clinical pharmacokinetics
 
Applications of pharmacokinetics parameters in disease states
Applications of pharmacokinetics parameters in disease statesApplications of pharmacokinetics parameters in disease states
Applications of pharmacokinetics parameters in disease states
 
Drug Therapy Monitoring
Drug Therapy MonitoringDrug Therapy Monitoring
Drug Therapy Monitoring
 
Biopharmaceutical & Pharmacokinetic consideration in the development of Contr...
Biopharmaceutical & Pharmacokinetic consideration in the development of Contr...Biopharmaceutical & Pharmacokinetic consideration in the development of Contr...
Biopharmaceutical & Pharmacokinetic consideration in the development of Contr...
 
Dose adjustment in Renal failure
Dose adjustment in Renal failure Dose adjustment in Renal failure
Dose adjustment in Renal failure
 
Methods to determine area under curve
Methods to determine area under curveMethods to determine area under curve
Methods to determine area under curve
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal Disorders
 
DESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptxDESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptx
 
Rate limiting steps in drug absorption
Rate limiting steps in drug absorptionRate limiting steps in drug absorption
Rate limiting steps in drug absorption
 
Dosing of drugs in liver failure
Dosing of drugs in liver failureDosing of drugs in liver failure
Dosing of drugs in liver failure
 

Destaque

Introduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimenIntroduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimenKLE College of pharmacy
 
Factors affecting pharmacokinetic parameters
Factors affecting pharmacokinetic parametersFactors affecting pharmacokinetic parameters
Factors affecting pharmacokinetic parametersJeffrey Pradeep Raj
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug MonitoringTulasi Raman
 
Trouble Shooting of Chemical Process Industry
Trouble Shooting of Chemical Process IndustryTrouble Shooting of Chemical Process Industry
Trouble Shooting of Chemical Process IndustryPankaj Khandelwal
 
Pharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseasesPharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseasesDr Htet
 
Pharmacokinetics In Special Populations
Pharmacokinetics In Special PopulationsPharmacokinetics In Special Populations
Pharmacokinetics In Special Populationspccampo
 
Pharmacokinetics (updated 2011) - drdhriiti
Pharmacokinetics (updated 2011)  - drdhriitiPharmacokinetics (updated 2011)  - drdhriiti
Pharmacokinetics (updated 2011) - drdhriitihttp://neigrihms.gov.in/
 
35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokineticsDang Thanh Tuan
 
Design and optimizing of dosage regimen - pharmacology
Design and optimizing of dosage regimen - pharmacology Design and optimizing of dosage regimen - pharmacology
Design and optimizing of dosage regimen - pharmacology Areej Abu Hanieh
 
Pilot plant scale up techniques used in pharmaceutical manufacturing
Pilot plant scale up techniques used in pharmaceutical manufacturingPilot plant scale up techniques used in pharmaceutical manufacturing
Pilot plant scale up techniques used in pharmaceutical manufacturingProf. Dr. Basavaraj Nanjwade
 
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & LactationPK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & LactationSreeja Saladi
 
Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014vanessawhitehawk
 

Destaque (20)

Introduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimenIntroduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimen
 
Obsity
ObsityObsity
Obsity
 
Factors affecting pharmacokinetic parameters
Factors affecting pharmacokinetic parametersFactors affecting pharmacokinetic parameters
Factors affecting pharmacokinetic parameters
 
Dosage Regimen
Dosage RegimenDosage Regimen
Dosage Regimen
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
Dosage regimen
Dosage regimenDosage regimen
Dosage regimen
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
Trouble Shooting of Chemical Process Industry
Trouble Shooting of Chemical Process IndustryTrouble Shooting of Chemical Process Industry
Trouble Shooting of Chemical Process Industry
 
Pharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseasesPharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseases
 
Renal Clearance
Renal ClearanceRenal Clearance
Renal Clearance
 
Pharmacokinetics In Special Populations
Pharmacokinetics In Special PopulationsPharmacokinetics In Special Populations
Pharmacokinetics In Special Populations
 
Pharmacokinetics (updated 2011) - drdhriiti
Pharmacokinetics (updated 2011)  - drdhriitiPharmacokinetics (updated 2011)  - drdhriiti
Pharmacokinetics (updated 2011) - drdhriiti
 
35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics
 
Design and optimizing of dosage regimen - pharmacology
Design and optimizing of dosage regimen - pharmacology Design and optimizing of dosage regimen - pharmacology
Design and optimizing of dosage regimen - pharmacology
 
Renal clearance
Renal clearanceRenal clearance
Renal clearance
 
Pilot plant scale up techniques used in pharmaceutical manufacturing
Pilot plant scale up techniques used in pharmaceutical manufacturingPilot plant scale up techniques used in pharmaceutical manufacturing
Pilot plant scale up techniques used in pharmaceutical manufacturing
 
excretion
excretionexcretion
excretion
 
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & LactationPK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
 
Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014
 
Pharmacokinetics of multiple dosing
Pharmacokinetics of multiple dosingPharmacokinetics of multiple dosing
Pharmacokinetics of multiple dosing
 

Semelhante a Pharmacokinetic variability

Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics Ahmad K
 
Analgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptxAnalgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptxDr.Vani Bais
 
Drug distribution in pediatrics
Drug distribution in pediatricsDrug distribution in pediatrics
Drug distribution in pediatricsNithin Jayan
 
Pediatric drug for clinical pharmacy student 1
Pediatric drug for clinical pharmacy student 1Pediatric drug for clinical pharmacy student 1
Pediatric drug for clinical pharmacy student 1Hussein Abdeldayem
 
Neonatal pediatric-pharmacology
Neonatal pediatric-pharmacologyNeonatal pediatric-pharmacology
Neonatal pediatric-pharmacologydunya
 
Drugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancyDrugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancyRoopali Somani
 
Individualization of drug dosage regimen
Individualization of drug dosage regimenIndividualization of drug dosage regimen
Individualization of drug dosage regimenDr. Ramesh Bhandari
 
Drug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatricsDrug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatricsTsegaye Melaku
 
Pediatric pharmacotherapy
Pediatric pharmacotherapyPediatric pharmacotherapy
Pediatric pharmacotherapyKaveh Kazemian
 
prescribing in paediatrics.pptx
prescribing in paediatrics.pptxprescribing in paediatrics.pptx
prescribing in paediatrics.pptxAraphaMvugalo
 
Drug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patientsDrug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patientsViraj Shinde
 
Clinical pharmacy age factors : Features of the Rational use of Medicines
Clinical pharmacy age factors : Features of the Rational use of MedicinesClinical pharmacy age factors : Features of the Rational use of Medicines
Clinical pharmacy age factors : Features of the Rational use of MedicinesEneutron
 
Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]DeepakGupta825
 
Paediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptxPaediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptx65NidheeshKumarPraba
 
Clinical trial in special population final
Clinical trial in special population finalClinical trial in special population final
Clinical trial in special population finalanupam raghunath
 
paeds drug drug calculation and formulas
paeds drug drug calculation and formulaspaeds drug drug calculation and formulas
paeds drug drug calculation and formulasPriyankaAnthony4
 
Principles of pharmacotherapy in neonates and paediatric population21
Principles of pharmacotherapy in neonates and paediatric population21Principles of pharmacotherapy in neonates and paediatric population21
Principles of pharmacotherapy in neonates and paediatric population21DrSatyabrataSahoo
 

Semelhante a Pharmacokinetic variability (20)

Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics
 
Drug therapy in children
Drug therapy in childrenDrug therapy in children
Drug therapy in children
 
Analgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptxAnalgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptx
 
Drug distribution in pediatrics
Drug distribution in pediatricsDrug distribution in pediatrics
Drug distribution in pediatrics
 
Pediatric drug for clinical pharmacy student 1
Pediatric drug for clinical pharmacy student 1Pediatric drug for clinical pharmacy student 1
Pediatric drug for clinical pharmacy student 1
 
Neonatal pediatric-pharmacology
Neonatal pediatric-pharmacologyNeonatal pediatric-pharmacology
Neonatal pediatric-pharmacology
 
Drugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancyDrugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancy
 
Individualization of drug dosage regimen
Individualization of drug dosage regimenIndividualization of drug dosage regimen
Individualization of drug dosage regimen
 
Individualization of drug
Individualization of drugIndividualization of drug
Individualization of drug
 
Drug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatricsDrug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatrics
 
Paediatrics
PaediatricsPaediatrics
Paediatrics
 
Pediatric pharmacotherapy
Pediatric pharmacotherapyPediatric pharmacotherapy
Pediatric pharmacotherapy
 
prescribing in paediatrics.pptx
prescribing in paediatrics.pptxprescribing in paediatrics.pptx
prescribing in paediatrics.pptx
 
Drug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patientsDrug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patients
 
Clinical pharmacy age factors : Features of the Rational use of Medicines
Clinical pharmacy age factors : Features of the Rational use of MedicinesClinical pharmacy age factors : Features of the Rational use of Medicines
Clinical pharmacy age factors : Features of the Rational use of Medicines
 
Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]
 
Paediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptxPaediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptx
 
Clinical trial in special population final
Clinical trial in special population finalClinical trial in special population final
Clinical trial in special population final
 
paeds drug drug calculation and formulas
paeds drug drug calculation and formulaspaeds drug drug calculation and formulas
paeds drug drug calculation and formulas
 
Principles of pharmacotherapy in neonates and paediatric population21
Principles of pharmacotherapy in neonates and paediatric population21Principles of pharmacotherapy in neonates and paediatric population21
Principles of pharmacotherapy in neonates and paediatric population21
 

Último

Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesFatimaKhan178732
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfJayanti Pande
 
Disha NEET Physics Guide for classes 11 and 12.pdf
Disha NEET Physics Guide for classes 11 and 12.pdfDisha NEET Physics Guide for classes 11 and 12.pdf
Disha NEET Physics Guide for classes 11 and 12.pdfchloefrazer622
 
The byproduct of sericulture in different industries.pptx
The byproduct of sericulture in different industries.pptxThe byproduct of sericulture in different industries.pptx
The byproduct of sericulture in different industries.pptxShobhayan Kirtania
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfchloefrazer622
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionSafetyChain Software
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationnomboosow
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityGeoBlogs
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13Steve Thomason
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 

Último (20)

Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and Actinides
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 
Disha NEET Physics Guide for classes 11 and 12.pdf
Disha NEET Physics Guide for classes 11 and 12.pdfDisha NEET Physics Guide for classes 11 and 12.pdf
Disha NEET Physics Guide for classes 11 and 12.pdf
 
The byproduct of sericulture in different industries.pptx
The byproduct of sericulture in different industries.pptxThe byproduct of sericulture in different industries.pptx
The byproduct of sericulture in different industries.pptx
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdf
 
Advance Mobile Application Development class 07
Advance Mobile Application Development class 07Advance Mobile Application Development class 07
Advance Mobile Application Development class 07
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory Inspection
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communication
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 

Pharmacokinetic variability

  • 1.
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7. Drug binding, metabolism, and excretion may change as a function of age.
  • 8. The study panel was divided into 5 groups: Newborns (2 to 3 days) Infants (1 to 12 months) Children (4 to 9 years) Adults (16 to 37 years) Elderly subjects (more than 70 years)
  • 9.
  • 10. Clearance increased from 0.9 to 2.5 ml/min. when comparing patient 1 to 8 days old with patient 9 to 30 days old.
  • 11. The mean clearance of ceftriaxone in children ranging in age from 1 to 12 months and from 1 to 6 years was 6.2 ml/min. and 9.1 ml/min. respectively.
  • 12.
  • 13.
  • 14. Most of the enzymatic microsomal systems required for drug metabolism are present at birth, but their concentration are usually lower than adult levels.
  • 15.
  • 16. Sulfate conjugation seems to be as efficient in newborns as in adults, but conjugation with glucuronic acid is considerably reduced, reaching adult level only after 3 years of age.
  • 17.
  • 18.
  • 19. In each case binding in plasma protein is level in the newborns than in the adults.
  • 20. Increase in plasma protein binding is an increase in apparent volume of distribution in the newborn.
  • 21.
  • 22.
  • 23. The difference process of renal excretion on mature at different rates,
  • 24. Average glomerular filtration rate is 38.5 ml/min.
  • 25.
  • 26.
  • 27. Older infants age (6 months to 12 years) has higher drug metabolism capacity rates compared to adults. for example, clindamycin theophylline valproic acid Has faster elimination rate.
  • 28.
  • 29. Formula used to determine dosage form
  • 30. Child dose= SA of child(m²) ------------------------------
  • 31.
  • 32. The increase in gastric ph, the decrease in gastric emptying rate and the slower motility associated with pregnancy can affect the rate and extent of drug absorption.
  • 33.